Detail of "30286-75-0"

Reference

Antibronchial disease compounds

Antibronchial disease compounds.There are some reagents like 30286-75-0 is used in this study. Bauer, Rudolf; Wick, Helmut (Boehringer Ingelheim G.m.b.H., Ger.). Can. CA 1022930 20 Dec 1977, 6 pp. (English). (Canada). CODEN: CAXXA4. NCL: 260-246. APPLICATION: CA 74-216754 24 Dec 1974. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Anticholinergic quaternary ammonium compds. are prepd. by quaternizing a base RNH with an alkyl bromide XBr in an org. solvent (e.g. EtOH, MeCN) to obtain RNX.Br [where: RN = benzilic acid 2-(N-ethylisopropylamino)-ethyl ester; (-)-N-ethyl-O-benzoylnorscopolamine or (-)-N-ethylnorscopolamine; and X = Me or Et). The compds. show good effects in treatment of bronchial diseases such as asthma, used on their own in inhalant compns. or mixed with other bronchospasmolytic substances. 30286-75-0 which is the cas registry number of some chemical is mentioned. Aerosol formulations are prepd. for inhalants. For example, an aerosol compn. for metered inhalant dispersers comprised N-ethylnorscopolamine methobromide (I) [30286-75-0] 0.007-0.7, sorbitan trioleate 0.05-2, and CFCl3-CF2Cl2 to give 100%. The amt. of I per dose was 5-500 mg. ..

Biochemical studies with oxitropium bromide

Biochemical studies with oxitropium bromide. 1. Pharmacokinetics and metabolism in rats and dogs. Wahl, D.; Foerster, H. J.; Pook, K. H.; Richter, I. (Abt. Biochem. Forschungsanal., Firma Boehringer Ingelheim K.-G., Ingelheim/Rhein 6507, Fed. Rep. Ger.). Arzneim.-Forsch., 35(1A), 255-65 (German) 1985. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) 14C-labeled oxitropium bromide [30286-75-0], a bronchospasmolytic, was tested pharmacokinetically in rats and dogs. Following oral administration low concns. of radioactivity persisting over several hours were measured in the blood. The active ingredient, which can be sepd. from the metabolites by TLC reaches a max. in the rat plasma after 1-2 h; it is then eliminated from the blood with a half-life of ~4 h. Following i.v. administration the radioactivity (active ingredient + metabolites) is distributed rapidly into the tissues. The distribution phase is followed by a relatively fast elimination phase ending in the terminal elimination phase ~1 h after administration. Rats and dogs eliminate the radioactivity mainly with the feces after oral administration, whereas following i.v. administration the rat eliminates about half with the feces and half via the kidneys. Biliary excretion in the rat is 12% after oral and 14% after i.v. administration. The rat absorbs 14% and the dog 28% of the dose. Five metabolites were demonstrated in the urine of both species. Metab. takes place exclusively in the tropaic acid part of the mol. and by hydrolysis of the compd.